Phibro Animal Health (NASDAQ:PAHC) Receives New Coverage from Analysts at Barclays

Barclays initiated coverage on shares of Phibro Animal Health (NASDAQ:PAHC) in a research note released on Tuesday morning, BenzingaRatingsTable reports. The brokerage issued an underweight rating and a $25.00 target price on the stock.

A number of other analysts have also commented on PAHC. Zacks Investment Research raised shares of Phibro Animal Health from a sell rating to a hold rating in a research report on Tuesday, February 12th. ValuEngine lowered shares of Phibro Animal Health from a hold rating to a sell rating in a research report on Wednesday, February 13th. BidaskClub lowered shares of Phibro Animal Health from a sell rating to a strong sell rating in a research report on Thursday, February 14th. Gabelli raised shares of Phibro Animal Health from a hold rating to a buy rating and set a $42.00 price objective on the stock in a research report on Wednesday, May 8th. They noted that the move was a valuation call. Finally, Guggenheim started coverage on shares of Phibro Animal Health in a research report on Thursday, May 23rd. They issued a neutral rating on the stock. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. Phibro Animal Health has a consensus rating of Hold and an average target price of $41.50.

Shares of PAHC stock opened at $29.01 on Tuesday. The company has a debt-to-equity ratio of 1.48, a quick ratio of 1.98 and a current ratio of 3.41. The firm has a market capitalization of $1.17 billion, a PE ratio of 16.67, a price-to-earnings-growth ratio of 4.37 and a beta of 0.74. Phibro Animal Health has a 12 month low of $27.32 and a 12 month high of $54.62.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Monday, May 6th. The company reported $0.39 EPS for the quarter, missing the Zacks’ consensus estimate of $0.43 by ($0.04). The business had revenue of $205.70 million during the quarter, compared to the consensus estimate of $214.94 million. Phibro Animal Health had a return on equity of 33.77% and a net margin of 8.12%. The business’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.46 EPS. Analysts anticipate that Phibro Animal Health will post 1.52 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 26th. Stockholders of record on Wednesday, June 5th will be given a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.65%. The ex-dividend date is Tuesday, June 4th. Phibro Animal Health’s dividend payout ratio is presently 27.59%.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Ceredex Value Advisors LLC increased its holdings in Phibro Animal Health by 5.8% during the first quarter. Ceredex Value Advisors LLC now owns 886,646 shares of the company’s stock worth $29,260,000 after buying an additional 48,694 shares during the last quarter. Foresters Investment Management Company Inc. increased its holdings in Phibro Animal Health by 12.0% during the fourth quarter. Foresters Investment Management Company Inc. now owns 601,233 shares of the company’s stock worth $19,336,000 after buying an additional 64,650 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Phibro Animal Health by 2.2% during the first quarter. Dimensional Fund Advisors LP now owns 542,922 shares of the company’s stock worth $17,916,000 after buying an additional 11,535 shares during the last quarter. Segall Bryant & Hamill LLC increased its holdings in Phibro Animal Health by 13.4% during the fourth quarter. Segall Bryant & Hamill LLC now owns 518,968 shares of the company’s stock worth $16,690,000 after buying an additional 61,134 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in Phibro Animal Health by 10.1% during the first quarter. Goldman Sachs Group Inc. now owns 500,901 shares of the company’s stock worth $16,530,000 after buying an additional 45,881 shares during the last quarter. Institutional investors and hedge funds own 50.25% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.

Recommended Story: How do analysts define an oversold condition?

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.